Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

884
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
884
Cancer Prevention02:59

Cancer Prevention

7.5K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
7.5K
Vaccinations01:51

Vaccinations

51.0K
Overview
51.0K
Preventive Healthcare Services01:30

Preventive Healthcare Services

1.8K
Preventive healthcare services keep people healthy via frequent check-ups, screening, and counseling. They primarily aid in disease prevention rather than treating an acute or chronic illness. Preventive treatment also keeps individuals productive and energetic, allowing them to work well into their retirement years. Examples of preventive care services include:
1.8K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.0K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.0K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

6.7K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
6.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An analysis of the registration of essential medicines in Namibia: a proxy measure of the availability of essential medicines.

Journal of pharmaceutical policy and practice·2026
Same author

Waiting times and admissions policies in England and Scotland before and after privatisation of services for NHS elective hip and knee replacement surgery in England between 2008 and 2019.

Health policy (Amsterdam, Netherlands)·2026
Same author

Outsourcing National Health Service Surgery to the Private Sector: Waiting Time Inequality and the Making of a Two-Tier System for Hip and Knee Replacement in England.

International journal of social determinants of health and health services·2025
Same author

Establishing links between drug registers and essential medicines lists.

Bulletin of the World Health Organization·2025
Same author

Sales and regulatory status of fixed dose combination psychotropic drugs in India: a retrospective longitudinal study.

Journal of pharmaceutical policy and practice·2024
Same author

Correction: Global Burden Disease Estimates for Major Depressive Disorders (MDD): A Review of Diagnostic Instruments used in Studies of Prevalence.

Community mental health journal·2024

Related Experiment Video

Updated: Dec 30, 2025

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

11.1K

Will HPV vaccination prevent cervical cancer?

Claire P Rees1, Petra Brhlikova2, Allyson M Pollock2

  • 1Centre for Global Public Health, Institute of Population Health Sciences, Barts and The London School of Medicine and Dentistry, Queen Mary University, London E1 2AB, UK.

Journal of the Royal Society of Medicine
|January 22, 2020
PubMed
Summary

Critical appraisal of human papillomavirus (HPV) vaccination trials reveals significant uncertainties. Current evidence is insufficient to confirm HPV vaccination efficacy in preventing cervical cancer due to trial design limitations and surrogate outcomes.

Keywords:
Vaccination programmescervical cancer

More Related Videos

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.8K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

28.0K

Related Experiment Videos

Last Updated: Dec 30, 2025

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
06:57

Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis

Published on: June 14, 2019

11.1K
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.8K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

28.0K

Area of Science:

  • Oncology
  • Vaccinology
  • Clinical Trial Analysis

Background:

  • Cervical cancer prevention strategies increasingly rely on human papillomavirus (HPV) vaccination.
  • Efficacy claims for HPV vaccines are based on Phase 2 and 3 clinical trials.
  • Critical appraisal is necessary to address uncertainties in vaccine efficacy data.

Purpose of the Study:

  • To critically appraise published Phase 2 and 3 efficacy trials of HPV vaccines (Cervarix and Gardasil).
  • To evaluate the certainty of evidence regarding HPV vaccination for cervical cancer prevention.
  • To identify limitations in trial design and outcome measures affecting efficacy conclusions.

Main Methods:

  • Systematic review and critical appraisal of 12 randomized controlled trials (RCTs) for Cervarix and Gardasil.
  • Analysis of trial populations, inclusion criteria, and surrogate outcome measures.
  • Assessment of data supporting prevention of cervical intraepithelial neoplasia (CIN) and cervical cancer.

Main Results:

  • Trial populations did not adequately represent target vaccination groups due to age and restrictive criteria.
  • Use of composite and surrogate outcomes (e.g., CIN1+) obscures clinically significant endpoints like CIN3+.
  • Evidence is insufficient to conclude HPV vaccination prevents cervical cancer; trials were not designed for this long-term outcome.

Conclusions:

  • Significant uncertainties exist regarding the efficacy of HPV vaccination in preventing cervical cancer.
  • Overdiagnosis of CIN due to frequent screening intervals may inflate efficacy estimates.
  • Further research with appropriate trial designs is needed to confirm long-term benefits.